Lucinactant

What is Lucinactant?[edit | edit source]

Lucinactant (SURFAXIN) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only.

SURFAXIN is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

Endogenous pulmonary surfactant lowers surface tension at the air-liquid interface of the alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures.
A deficiency of pulmonary surfactant in premature infants results in RDS.
SURFAXIN compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.

Recommended dosage:

Administration:

For intratracheal administration only.
SURFAXIN should be administered by or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.
Administration-Related Adverse Reactions may occur. If adverse reactions including bradycardia, oxygen desaturation, reflux of SURFAXIN into the endotracheal tube (ETT), and airway/ETT obstruction occur during administration of SURFAXIN, dosing should be interrupted and the
infant’s clinical condition assessed and stabilized. Suctioning of the ETT or reintubation may be required if airway obstruction persists or is severe.
Adults with ARDS who received lucinactant via segmental bronchoscopic lavage had an increased incidence of death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, and pulmonary embolism. SURFAXIN is not indicated for use in ARDS

There have been no reports of overdose following the administration of SURFAXIN.

Treatment of overdosage:

If respiration, ventilation, or oxygenation is clearly affected after an accidental overdose, aspirate as much of the suspension as possible and provide the infant with supportive treatment.

It can be used up to two years of age and is specified for children who are diagnosed with acute respiratory failure following exposure to a pathogen such as RSV or influenza, including H1N1.

Store SURFAXIN in a refrigerator at 2° to 8°C (36° to 46°F) and protect from light until ready for use.
Do not freeze.
Vials are for single use only.
Discard any unused portion of SURFAXIN.
Discard warmed vials of SURFAXIN if not used within 2 hours of warming.

Lucinactant Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.